Stocklytics Platform
ARCA biopharma
ABIO48
$25.470.00%$0.00
NASDAQ - As of Apr 16, 12:10 AM EDT Market Closed
ABIO48

$25.47

0.00%

Performance History

Chart placeholder
Key Stats
Open$24.95
Prev. Close$25.47
EPS-5.88
Dividend$20.67
Next Earnings Date-
Dividend Yield %-
Market Cap$34.81M
PE Ratio-
LOWHIGH
Day Range24.50
25.62
52 Week Range18.72
53.88
Ratios
P/B Ratio1.07
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %46.21%
EBITDA Margin %-
ROE %-20.05%
EPS-5.88

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Correlated Companies

Eli Lilly & Co
LLY84
Price$757.18
Perf. (24h)arrow_drop_up0.61%$4.64
Market Cap$680.07B
UnitedHealth Group
UNH69
Price$583.59
Perf. (24h)arrow_drop_down0.86%-$5.05
Market Cap$538.89B
Johnson & Johnson
JNJ61
Price$153.62
Perf. (24h)arrow_drop_down0.39%-$0.61
Market Cap$397.30B
AbbVie
ABBV67
Price$176.80
Perf. (24h)arrow_drop_down1.28%-$2.29
Market Cap$312.75B

About ARCA biopharma (ABIO)

ARCA biopharma Inc (ABIO) is a biopharmaceutical company that focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's primary focus is on developing therapies for atrial fibrillation (AFib), which is a common type of arrhythmia that affects millions of people worldwide. ARCA's lead product candidate, AB201, is designed to treat AFib by targeting a specific genetic mutation known as G protein beta-3 (GNB3). This mutation is believed to be a key driver of AFib and is present in a significant percentage of patients with the condition.
In recent years, ARCA has made significant progress in the development of AB201. The company has successfully completed several clinical trials, demonstrating the safety and efficacy of the drug in patients with AFib. These trials have shown that AB201 can effectively restore normal heart rhythm and reduce the risk of AFib-related complications. In addition to AFib, ARCA is also exploring the potential of AB201 in other cardiovascular diseases, such as heart failure.
Show more
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Michael R. Bristow M.D., Ph.D.
Headquarters
Westminster
Employees
5
Exchange
NASDAQ
add ARCA biopharma to watchlist

Keep an eye on ARCA biopharma

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the 52-week high and low for ARCA biopharma (ABIO)?

For ARCA biopharma (ABIO), the 52-week high is $53.88, which is 111.54% from the current price. The 52-week low is $18.72, the current price is 36.06% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

What is ARCA biopharma 's (ABIO) price per share?

The current price per share for ARCA biopharma (ABIO) is $25.47. The stock has seen a price change of $0 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.
help

Is ARCA biopharma (ABIO) a growth stock?

ARCA biopharma (ABIO) has shown an average price growth of -1.65% over the past three years. It has received a score of 98 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying ARCA biopharma as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is ARCA biopharma (ABIO) stock price performance year to date (YTD)?

As of the latest data, ARCA biopharma (ABIO) has a year-to-date price change of . Looking at a longer horizon, the five-year price change stands at -43.25%.
help

Is ARCA biopharma (ABIO) a profitable company?

ARCA biopharma (ABIO) has a net income of -$5.34M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$7.3M. Furthermore, the EBITDA is $214.57M.
help

What is the market capitalization of ARCA biopharma (ABIO)?

ARCA biopharma (ABIO) has a market capitalization of $34.82M. The average daily trading volume is 86.69K, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level